Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sales of Ethical Drugs Up 3.8% in November 2010
January 31, 2011
- NIBIO Reports Efficient Generation of Hepatoblasts from iPS Cells
January 31, 2011
- Korosho Withholds Approval of Norspan
January 31, 2011
- Top-Four Generics-Only Firms Expand Production Capacity
January 31, 2011
- PAFSC Committee Recommends Halaven for Approval
January 31, 2011
- TAIYO Pharm. Recalls Two Generics
January 31, 2011
- Dasen to Be Re-designated for Reevaluation
January 31, 2011
- Korosho to Consider Diabetes Treatment Strategy Using Incretin-Related Drugs
January 31, 2011
- Nichi-Iko to Transfer More Long-Listed Original Products to Nichi-Iko sanofi-aventis
January 31, 2011
- AZ Refuses Compromise Proposed by Courts over Iressa Lawsuits
January 31, 2011
- NICE Recommends Aricept for Mild AD as Well
January 31, 2011
- 70% of Women Would Like to Be Vaccinated against Cervical Cancer
January 31, 2011
- Kowa Applies for Peretinoin in Japan
January 31, 2011
- MSD to Propose Its Own Anti-Allergy Drugs Alone or in Combination for Pollinosis
January 31, 2011
- Yasuchika Hasegawa to Step Down as JPMA President, Isao Teshirogi to Succeed
January 31, 2011
- Korosho Cautions on the Use of Botulinum Toxin Types A, B
January 31, 2011
- Dialysis Costs Kyokaikenpo ¥175 Bil. Annually
January 31, 2011
- JPMA to Finalize GL for Disclosure of Funds Offered to Medical Institutions
January 31, 2011
- PMDA to Transfer GMP Compliance Inspection Power Earlier to Prefectures
January 31, 2011
- Sanofi-aventis Signs R&D Collaboration Agreements with UCSF
January 31, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…